Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful.
Gervais L, McLean LL, Wilson ML, Cameron C, Curtis L, Garrick V, Armstrong K, Tayler R, Henderson P, Hansen R, Chalmers I, Wilson DC, Russell RK.
Gervais L, et al. Among authors: mclean ll.
J Pediatr Gastroenterol Nutr. 2018 Dec;67(6):745-748. doi: 10.1097/MPG.0000000000002091.
J Pediatr Gastroenterol Nutr. 2018.
PMID: 29985877
Free article.